Agitation in Delirium Management Market, By Drug Type (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines), By Route of Administration (Oral, Intramuscular, Others), By Distribution Channel (Hospital Pharmacies, Retail Phar

Agitation in Delirium Management Market, By Drug Type (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines), By Route of Administration (Oral, Intramuscular, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Delirium is commonly associated with myriad conditions and requires a variety of medications. Early recognition and on-time treatment can help reduce morbidity, length of hospital stay, health care costs, and mortality in patients. According to Marie Curie, a registered organization in the U.K. that provides nursing and hospice care to elderly patients, they have mentioned on their website that many patients develop delirium in the last few days of their lives, which can cause agitation or restlessness. This is sometimes called terminal restlessness or terminal agitation. First-generation antipsychotics are the first choice of treatment for agitation in delirium management patients, followed by second-generation antipsychotics and benzodiazepines. Delirium is a serious change in mental abilities. It results in confused thinking and a lack of awareness of someone's surroundings. The disorder usually comes on fast, within hours or a few days. Delirium can often be traced to one or more factors. Factors may include a severe or long illness or an imbalance in the body, such as low sodium. The disorder may also be caused by certain medicines, infection, surgery, or alcohol or drug use or withdrawal.

Market Dynamics

Increasing research and development activities by key market players is expected to drive the global agitation in delirium management market growth over the forecast period. For instance, on September 11, 2023, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced that they had started a clinical trial for Ramelteon (Rozerem), a central nervous system (CNS) depressant and hypnotic. It is formulated as film-coated tablets and coated tablets for oral route of administration.

Key features of the study:

• This report provides an in-depth analysis of the global agitation in delirium management market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global agitation in delirium management market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., BioXcel Therapeutics, Inc., and Takeda Pharmaceutical Company Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global agitation in delirium management market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global agitation in delirium management market

Detailed Segmentation:

• By Drug Type:
• First-generation Antipsychotics
• Second-generation Antipsychotics
• Benzodiazepines
• By Route of Administration:
• Oral
• Intramuscular
• Others
• By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Company Profiles
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Limited
• Mylan N.V.
• Fresenius Kabi AG
• Novartis AG
• Akorn Incorporated
• Zydus Cadila
• Pfizer, Inc.
• BioXcel Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited